Science and Technology : Releasing Genetically Modified Mosquitoes

Discussion in 'Science and Technology' started by UBNaturally, Oct 18, 2014.

  1. UBNaturally

    UBNaturally Well-Known Member MEMBER

    United States
    Jan 15, 2014
    Likes Received:
    Press Release: Moscamed prepares for next phase in the development of Oxitec’s transgenic mosquitoes in Brazil
    Oxitec Ltd 10th July 2012

    9 July 2012

    Following successful open release trials in Brazil, Moscamed are now gearing up for the next phase of development in combatting the mosquitoes which spread dengue fever, with the launch of their new mosquito production facility. On Saturday 7 July 2012 Moscamed formally opened their new facility, which will enable production of Oxitec’s mosquitoes to be scaled up to an initial level sufficient for a town of approximately 50,000 people. The opening was attended by the Minister of Health of Brazil, Alexandre Padilha. Other attendees were Jorge Solla the Secretary of Health of the State of Bahia, Paulo Camer the Secretary of Science, Technology and Innovation of State of Bahia and Manuel Barral representing Ministry of Science and Technology.


    PRESS RELEASE: Moscamed launches urban scale project using Oxitec GM mosquitoes in battle against dengue
    Tracy Thompson 20th June 2013

    Oxitec, Oxford, UK 20th June 2013

    Today Moscamed made the first releases of Oxitec GM mosquitoes to mark the launch of a new programme to control the dengue mosquito Aedes aegypti in the town of Jacobina in the State of Bahia.

    In previous trials Moscamed have demonstrated that, using the Oxitec mosquitoes, it is possible to rapidly reduce the number of dengue mosquitoes in a town. In the most recent demonstration in Mandacaru the level of these mosquitoes were reduced by 96% within 6 months and it was shown that this reduction could be maintained for many months including through the time of the year when normally mosquito levels would be at their peak.


    Fruit fly Companies in Liberia


    Oxitec Ltd

    Oxitec is a pioneer in controlling insects that spread disease and damage crops. Through world class science we have developed an innovative new solution to controlling harmful insects pests. Oxitec is a British biotech company pioneering a better approach to tackling dengue fever and damaging agricultural pests.Dengue is a growing global problem.

    The British biotech company is pioneering a better approach to tackling dengue fever and damaging agricultural pests, by using advanced genetics to develop a new solution to controlling populations of the dengue mosquito and other harmful insects in a way that is sustainable, environmentally friendly and cost-effective.

    Oxitec breeds and releases ‘sterile’ males of the damage-causing species. This highly targeted form of biological control is safe to other species, causes no lasting impact on the environment and is cost-effective.



    Oxitec does basic research and creates product candidates at its laboratories in the UK. Optimised candidates are evaluated and tested in laboratory and field settings in conjunction with partners.

    See more at:

    Alarm at new dengue emergency where GM mosquito trials conducted

    July 8, 2014

    Civil society groups today expressed alarm at an increase in dengue incidence, leading to an emergency decree, in a town in Brazil where releases of genetically modified (GM) mosquitoes are taking place.

    The promise was to create genetically modified mosquitoes that would end dengue, but results from field trials conducted in Bahia, Brazil have not been published to date and did not evaluate the relation between Aedes aegypti mosquito populations and the occurrence of dengue. Nevertheless, the Brazilian regulator Comissão Técnica Nacional de Biossegurança (CTNBio) recently gave the green light to the commercialization of the technology proposed by Moscamed Brazil in partnership with the English company Oxitec and the Universidade de São Paulo.


    The Brazilian press had welcomed the new weapon to combat dengue but missed the information that Jacobina's mayor, a locality where the trials took place, issued a decree in February 2014 renewing the state of emergency "due to the abnormal situation characterized as a biological disaster of dengue epidemic."


    The Brazilian National Agency of Sanitary Vigilance (ANVISA) is now in charge of registering and monitoring the product, which according to the company's recommendation implies weekly releases of 10 million GM mosquitoes for every 50 thousand inhabitants. Meanwhile, the date of publication of the promised results remains unclear.